BioCryst Pharmaceuticals Sees Revenue Near Top of Guidance as It Expands HAE Portfolio

Résumé détaillé
BioCryst Pharmaceuticals (NASDAQ:BCRX) expects revenue to land at the upper end of its $625 million to $645 million guidance range this year, CEO Charlie Gayer said at a Jefferies…
BioCryst Pharmaceuticals (NASDAQ:BCRX) expects revenue to land at the upper end of its $625 million to $645 million guidance range this year, CEO Charlie Gayer said at a Jefferies conference, while outlining plans to expand its hereditary angioedema portfolio and add rare-disease assets.
Gayer said the company expects continued growth for ORLADEYO, its oral treatment for preventing hereditary angioedema (HAE) attacks, although he anticipates growth will eventually plateau as additional competitors enter the market. BioCryst also expects pivotal data next year for navenibart, an investigational injectable treatment for HAE.
→ The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Gayer said more than 1,600 U.S. patients are taking ORLADEYO, which has been on the market since late 2020, and that more than 1,500 U.S. clinicians have prescribed it this year. The company has been adding more than 60 prescribers per quarter, he said.
Addressing the prospect of competition from another oral prophylactic treatment, deucrictibant, Gayer argued that patients who remain on ORLADEYO experience strong effectiveness. In the APeX-2 study, just over half of patients who started on the 150-milligram dose remained on treatment for two years, and those patients had a 91% reduction in attacks, he said.
In real-world use, about 60% of patients remain on treatment at 12 months, with insufficient effectiveness the leading reason for discontinuation, Gayer said. Among patients with type 1 or type 2 HAE taking ORLADEYO who reported on the preceding six months, 44% reported no attacks and about 70% reported two or fewer, he said.
Gayer said BioCryst's annual market research suggests patients doing well on ORLADEYO will remain on it despite new alternatives. He estimated the drug's current share at 22% to 23% across all treated HAE patients, rather than only those receiving preventive therapy, and said BioCryst expects that share to grow into the mid-20% range before leveling…
Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)



